Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

View/Open

Supporting information (63.31Kb)

Publication Date

2017-05

ICR Author

Larkin, James

Marsden,

Author

Dreno, B

Ribas, A

Larkin, J

Ascierto, PA

Hauschild, A

Thomas, L

Grob, J-J

Koralek, DO

Rooney, I

Hsu, JJ

McKenna, EF

McArthur, GA

Type

Journal Article

Metadata

Show full item record

URL

https://repository.icr.ac.uk/handle/internal/1473

Collections

• Clinical Studies

Version of record

10.1093/annonc/mdx040

Subject

cobimetinib

MEK inhibition

melanoma

safety

Research team

Melanoma and Kidney Cancer

License start date

2017-05

Citation

ANNALS OF ONCOLOGY, 2017, 28 (5), pp. 1137 - 1144